CASIMERSEN - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for casimersen and what is the scope of freedom to operate?
Casimersen
is the generic ingredient in one branded drug marketed by Sarepta Theraps Inc and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.Casimersen has eighty-seven patent family members in twenty-four countries.
One supplier is listed for this compound.
Summary for CASIMERSEN
International Patents: | 87 |
US Patents: | 6 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Clinical Trials: | 3 |
What excipients (inactive ingredients) are in CASIMERSEN? | CASIMERSEN excipients list |
DailyMed Link: | CASIMERSEN at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for CASIMERSEN
Generic Entry Date for CASIMERSEN*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for CASIMERSEN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Sarepta Therapeutics, Inc. | Phase 2 |
Kevin Flanigan | Phase 2 |
Sarepta Therapeutics | Phase 3 |
Pharmacology for CASIMERSEN
Drug Class | Antisense Oligonucleotide |
Physiological Effect | Increased Protein Synthesis |
Anatomical Therapeutic Chemical (ATC) Classes for CASIMERSEN
US Patents and Regulatory Information for CASIMERSEN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sarepta Theraps Inc | AMONDYS 45 | casimersen | SOLUTION;INTRAVENOUS | 213026-001 | Feb 25, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Sarepta Theraps Inc | AMONDYS 45 | casimersen | SOLUTION;INTRAVENOUS | 213026-001 | Feb 25, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Sarepta Theraps Inc | AMONDYS 45 | casimersen | SOLUTION;INTRAVENOUS | 213026-001 | Feb 25, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Sarepta Theraps Inc | AMONDYS 45 | casimersen | SOLUTION;INTRAVENOUS | 213026-001 | Feb 25, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CASIMERSEN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Sarepta Theraps Inc | AMONDYS 45 | casimersen | SOLUTION;INTRAVENOUS | 213026-001 | Feb 25, 2021 | ⤷ Sign Up | ⤷ Sign Up |
Sarepta Theraps Inc | AMONDYS 45 | casimersen | SOLUTION;INTRAVENOUS | 213026-001 | Feb 25, 2021 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CASIMERSEN
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
European Patent Office | 2305200 | Parure de transfert d'occupant (Occupant transfer topper) | ⤷ Sign Up |
European Patent Office | 4047096 | OLIGONUCLÉOTIDES ANTISENS POUR INDUIRE L'OMISSION DE L'EXON ET LEURS PROCÉDÉS D'UTILISATION (ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF) | ⤷ Sign Up |
China | 103003430 | Antisense molecules and methods for treating pathologies | ⤷ Sign Up |
South Korea | 20130084595 | ANTISENSE MOLECULES AND METHODS FOR TREATING PATHOLOGIES | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.